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As a newly emerging pattern of consumption and production of healthcare services, medical tourism is 
featured with particular regional characteristics in the range of service for patients elect to travel across 
international borders with the intention of receiving medical treatment. From perspectives of globalization and 
supply consideration, this article illustrates the drives, size and scope of medical tourism. Experiences from 
Korea and UK are introduced to explain commonalities and distinctions of diverse medical tourism treatments 
and their destinations. In addition, the authors also illustrate payment mechanism, potential challenges and 









Across the world there are newly emerging patterns of consumption and 
production of healthcare services.  These arise from the global flows of 
patients and healthcare professionals (doctors, nurses and allied healthcare 
staff), medical technology, capital funding and regulatory regimes 
(standards and accreditation) across national borders.   
 
Particular attention has been paid to flows of patients 
who are being treated outside of their national 
jurisdiction.  Patients, it would appear, are on the move 
and so-called medical tourism is on the rise.  Medical 
tourism may be defined as when patients elect to travel across international 
borders with the intention of receiving medical treatment.  Included within the 
definition are a broad range of medical services and innovations: dental care, 
cosmetic surgery, elective surgery, fertility treatment, transplantation, and 
stem cell therapy.  
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Setting the boundary of what is health and counts as medical tourism is not straightforward. For 
example, cosmetic surgery for aesthetic rather than reconstructive reasons would be considered 
outside the health boundary under OECD definitions for the purposes of trade accounts (OECD, 
2010, pp. 30-31).  Similarly, stem cell therapies are distinguished from stem cell treatments when 
there is lack of clinical efficacy data and supporting evidence.  
 
Medical tourism in some European settings is related to the broader notion of health tourism which, 
in some countries, has longstanding historical antecedents of spa towns and coastal localities, and 
other therapeutic landscapes. In countries such as Hungary this strong wellness tourism tradition 
continues alongside the development of medical treatments and interventions. Within a number of 
Asian settings, Oriental medicine is a major specialty that is offered.  Clearly, the range of services 
sought and offered has a particular regional texture and as research scholarship develops it is 
beginning to understand far more the commonalities and distinctions of diverse medical tourism 
treatments and their destinations. 
 
The size and scope of medical tourism 
 
Some places may be simultaneously acting as countries of origin and destination in a medical 
tourism marketplace. High-income countries may treat overseas elites whilst at the same time their 
citizens choose to travel as medical tourists to Lower and Middle Income Countries for treatments. 
Thus, Harley Street in the UK and facilities including the Mayo and Cleveland Clinics in the United 
States have longstanding reputations in the international provision of healthcare.  But UK and US 
patients themselves travel outwards for treatments subject to a range of push and pull 
considerations.   
 
Drivers of medical tourism include dimensions of globalisation – economic, social, cultural and 
technological.  Many domestic health systems are undergoing significant challenges and strain – 
heightened expectations, tightened eligibility criteria, waiting lists, and shifting priorities for health 
care may all contribute. The role of Information Technology in promoting new products and 
information, as well as greater availability of air travel and travel visas are also significant.  Medical 
tourists may be diaspora or second-generation migrants, and liable to travel back to countries 
where there are historical, cultural and familial connections.  Familiarity, availability, price, quality 
and legality may thus all be factors within complex decision-making frames of medical tourists.  
 
There are also supply considerations. For example, as economic growth slows in western 
industrialised countries and austerity bites, public and private healthcare organisations are seeking 
additional income from a range of sources, including international patients. A range of national 
policy characteristics will shape the involvement of domestic healthcare providers in delivering 
treatments to medical tourists including: 
 
 the regulatory framework (including the lack of one) which may present constraints on the 
services that may be offered to inward patients;   
 state and regional support for the development of medical tourism; 
 professional bodies’ support and involvement within medical tourism; 
 the structure of health care provision (e.g. sole practitioner practices; entrepreneurial 
approaches and less socialized approaches to medicine);  
 cultural and ethical standpoints of providers on offering particular treatments; some providers 
may be prepared to offer treatments that are more risky, or to place different emphasis on the 
ethical issues involved; 







 health care reform and existing capacity within systems will dictate, to a large extent, whether 
providers will engage in treating overseas patients; 
 the role of national/international quality frameworks may shape the way in which countries 
engage; 
 the willingness of professionals to treat individuals who lie out with safety guidelines and normal 
professional criteria (age, weight, medical history). Thus, are particular treatments offered that 
would not routinely be offered by providers in the same country or in overseas countries? (Lunt 
et al., 2013a) 
 
Despite the global push for many countries to offer both high-end and/or relatively low-cost 
treatments, we currently know very little about many of the key features of medical tourism.  There 
are no authoritative data on the number and flow of medical tourists between nations and 
continents. So although there is broad agreement that the medical tourism industry has grown 
significantly over the past decade, there is wide speculation on its actual size.  The Deloitte 
management consultancy for example suggested a figure that has been regularly reproduced in 
the literature, that total worldwide figures lie somewhere between 30 and 50 million medical tourists 
travelling for treatment each year (Ehrbeck et al., 2008). Even where commentators avoid placing 
a figure on the number of medical tourists, the frequent citation of medical tourism as a $60bn 
industry can be traced back to Deloitte’s report (MacReady, 2007; Crone, 2008; Keckley and 
Underwood, 2008; for criticism see Connell, 2013 and Lunt et al., 2013b). 
 
Medical tourist destinations differ in how much they openly promote the cultural, heritage and 
recreational opportunities. It is likely that for some treatments the vacation and convalescence 
functions will be more marginal, for others it could be a more significant component of consumer 
decision-making.  The reputation of places as highly customer-focused service providers is also a 
prevalent focus of advertising.  An emphasis on marketing services as high technology and high 
quality is common, as well as identifying clinicians that have overseas experience (training, 
employment, registration). 
 
The experiences of Korea and the UK 
 
Medical tourism as an emerging global industry has a range of commercial interests including 
health care providers, website providers, brokers and facilitators, accommodation, and 
conference and media services (See Figure 1). A range of national government agencies are also 
involved and policy initiatives have sought to stimulate and promote medical tourism in their 
countries (these include countries as diverse as Korea and the UK). Within Asia (for example, 
Thailand, India, Singapore, Malaysia), Europe (including Hungary and Poland) and beyond, 
governments promote their comparative advantage as medical tourism destinations at large 
international trade fairs, via advertising within the overseas press, and official support for activities as 
part of their economic development and tourism policy (see Lunt et al., 2011; Reisman, 2010). 
 





























Faced with global economic recession and an aging population, the Korean Government sought 
to find ways to boost the economy and after 2009 the Korean Government allowed 
hospitals/clinics to fully market health services to foreign patients. The process of promoting the 
medical tourism industry was expected to generate job opportunities and be a new growth engine 
for economic development. To this end a medical visa was also adopted (Yu and Ko, 2012; Kim et 
al., 2013). 
 
The actual development and delivery of medical tourism policy is undertaken by public 
organizations including Korea Health Industry Development Institute (KHIDI) and the Korea Tourism 
Organization. KHIDI, under the Ministry of Health and Welfare has two purposes: to improve the 
national health industry by providing comprehensive and professional support programmes; and 
second, to strengthen the competitiveness of the national health industry. Its department of 
international cooperation has five teams actively involved in promoting medical tourism (see also, 
Kim et al., 2013). 
 
Domestically many Korean medical institutions and leading hospitals and clinics have supported 
the venture. Particularly, they sought to increase revenues by treating foreign patients, charging 
premiums far above domestic insurance rates. Participating providers hoped that treating foreign 
patients would bolster their domestic reputation for medical excellence, and there were 
anticipated benefits for improving service quality, because many medical institutions in Korea are 
accredited by Joint Commission International.  Under Korean law, any medical institutions that 
intend to treat foreign patients are required to be registered by the Ministry of Health and Welfare. 
Within Korea, the percentage of medical institutions registered has increased from 2.6% to 3.6% 
between 2009 and 2011. Nearly 98% of tertiary hospitals are registered. 
 
Table 1: Source country of medical tourists to Korea 2009-2011 
 
Nation 2009 2010 2011 Average 
growth rate (%) 
USA 13,976 (32.6%) 21,338 (32.4%) 27,529 (27.1%) 40.3 
Japan 12,997 (30.3%) 11,035 (16.8%) 22,491 (22.1%) 31.5 
China 4,725 (11.0%) 12,789 (19.4%) 19,222 (18.9%) 101.7 
Russia 1,758 (4.1%) 5,098 (7.7%) 9,651 (9.5%) 134.3 
Mongolia 850 (2.0%) 1,860 (2.8%) 3,266 (3.2%) 96.0 
Source: Statistics on International Patients in Korea, 2011 (KHIDI) 
 
Within the UK, measures to support international activities of the public health system (to treat 
private international patients in parallel to public taxpayer funded UK patients) include NHS Global 
established in 2010, and the launch of the Healthcare UK Scheme in 2012 promoting wider health 
interests.  Attempts to attract international patients must be placed in the wider context of 
countries offering a suite of expertise and services – consultancy, training, and education around 
health provider development and delivery. 
 
How treatment is funded 
 









 Outsourced patients  
Those are patients opting to be sent abroad by health agencies using cross-national purchasing 
agreements. Typically, these sorts of agreements are a short-term measure driven by long 
waiting lists and a lack of available specialists and specialist equipment in the home country. 
Middle-East countries including Kuwait, UAE and Saudi Arabia support patient to travel to 
countries in Europe including Germany and the UK.  Plausibly, the health systems within source 
countries (including UK, Germany and the United States) could develop relations with off-shore 
medical tourism facilities to leverage cost savings – providing individuals with a choice of 
overseas destinations. This could also reduce waiting lists – and reflects a form of outsourcing or 
more ‘collective’ medical travel. However, even if opportunities for financial benefit exist and 
medical tourism is an option in a number of countries there are significant political objections 
and sensitivities. This for example helps explain why Medicaid and Medicare in the United States 
do not support patients travelling abroad for treatments despite arguments that doing so would 
deliver significant financial savings. 
 
 Individual out-of-pocket payments for treatment 
People who want access to private treatment can afford it themselves, drawing on income, 
savings, loans, and family and community support.   
 
 Insurance 
A potentially lucrative source of income is private and workplace health insurance systems.  To 
date there has been relatively limited success by medical tourist providers in tapping these 
insurance revenue streams.  Most insurance policies in the UK for example explicitly exempt 
overseas treatment, whilst standard policy exclusions include conception, cosmetic, 
reconstructive or weight loss treatment and dental/oral treatment. These are the sorts of 
treatments where evidence suggests patients then choose pay out of pocket, both 
domestically and abroad.  Within the United States, examples of more institutionalised 
arrangements do exist but are rare. In 2009, following its achieving international accreditation, a 
hospital in Mexico arranged a deal with a US-based insurance group which enabled Blue Cross 
and Blue Shield members to utilise that hospital‘s services. Singapore is one example of a 
country that has allowed some portability with insurance. 
 
Evidence base for medical tourism 
 
Despite the huge amount of speculation and expectations around medical tourism hard evidence 
on many aspects is difficult to find (see Lunt and Carrera, 2010 for review). Alongside the dearth of 
empirical data is the tendency for discussions to be focussed on marketing and market growth, 
without being critical of assumptions.  Fortunately this gap is beginning to be addressed and 
scholarship has encompassed discussion of North American (Crooks et al., 2010; Johnson and 
Garman, 2010), Australasian (Barrowman et al., 2010), Asian (NaRanong and NaRanong, 2011; 
Pocock and Phua, 2011; Wongkit and McKercher, 2013) and European contexts (Hanefeld, et al, 
2013; Legido-Quigley at al., 2011).  Within the UK, a national-funded study is soon to report on the 
implications of medical tourism for the NHS (see Lunt et al., 2013c)  
 
Emerging challenges: clinical and programme levels  
 
The policy, programme and clinical recommendations concerning medical tourism should be 









As well as patient motivations, decision-making, experience and satisfaction, this should include 
understanding of treatment outcomes. How patient information flows across national boundaries is 
an important question for the medical tourism industry, with continuity of care affected if patient 
records are not shared. Patients should receive appropriate information, advice and input at all 
stages of the caring process. This includes informed consent and advance warning that redress 
may be more difficult if treatment is received outside of country of residence. Whilst ethical and 
legal issues arise for all forms of medical care – informed consent, liability and legislating for clinical 
malpractice – these are intensified for medical tourism. ‘Cosmetic tourism’, ‘fertility tourism’, 
‘transplant tourism’, to say nothing of recent developments in the areas of ‘stem cell’-tourism’ and 
‘euthanasia tourism’, raise ever-more complex medico-legal and ethical questions.  
 
Legal dilemmas for medical tourists include that pursuing a case overseas brings particular 
difficulties. Should complications arise during medical tourism, patients may not be covered by 
insurance or indemnity policies that are carried by the hospital, the surgeon or physician treating 
them, and they may have little recourse to local courts or medical boards. One reason US health 
care is so expensive is the size of malpractice premiums, an indication that US citizens are litigious 
and value their right to seek legal redress. 
 
The public health aspects of medical tourism have not been adequately studied. Of significance is 
the potential for hazardous micro-organisms transferring between hospitals located in different 
parts of the world on the body of a medical tourist (Green, 2008; Lunt et al., 2012). These could 
include antimicrobial resistance, such as the potential for Clostridium difficile, VRSA, XDRTB, or a 
dangerous pathogen, such as SARS. 
 
Given asymmetries of information in healthcare, patients place significant trust in training, 
qualifications, motivations and competence of health care professionals. When we step outside our 
national health system questions arise concerning robust clinical governance arrangements and 
quality assurance procedures in provider organisations, intended to safeguard the quality of care 
provided.  
 
System level challenges 
 
Countries seeking to develop medical travel earnings have options of growing their own health 
service (public and private) or inviting partnerships with large multinational players. Securing 
accreditation from international programmes may be a part of the development of services and 
an attempt to badge quality.  Achieving partnerships with overseas hospitals and universities (e.g. 
Asian countries’ relations with the American private sector), can fulfil a similar role. We need to 
know far more about these relationships across the globe. 
 
Patients travelling to countries with developed healthcare systems raise important questions for 
comparative healthcare policy and management. Knowing more about revenue generation 
(health treatment and wider associated non-health income) and whether infrastructural 
investments and favourable spill-overs benefit local patients is important.  Does trickle down of best 
practice occur and can we identify processes of technological transfer and surgical learning? 
Similarly, what is the impact on staff retention (international/internal brain retention and return) of 
such medical tourism activities (see Lunt et al., 2013a)? 
 
The lack of data is problematic if countries are to keep fully informed about the significance 
(potential or actual) of medical tourism for their health systems. Mechanisms are needed that help 







where and for what?  Currently, the evidence base is scant to enable us to assess winners and 




Turning to China: what is the emerging evidence about inward and outward flows? As an importer 
of medical tourists we know relatively little of the developments despite a number of institutions 
aiming to treat overseas patients.  This knowledge base may develop with the establishment of the 
Shanghai International Medical Zones after 2015.  Regarding outflows, some evidence is beginning 
to emerge, regarding relationships with Taiwan (Liu, 2012), Hong Kong (Ye et al., 2011) and Korea 
(KHIDI, 2011).  There has been a steady growth of travellers to Korea from 4,725 in 2009 to 19,222 in 
2011 (KHIDI, 2011). Over 70% of Chinese patients to Korea are women, and a large percentage is 
aged 20 to 39. China is first ranked in plastic surgery, where Chinese patients occupy nearly 59% of 
market share in Korea.  The challenge is to build on this emerging scholarship more systematically 
and conceptually.  Certainly, the future of medical tourism regionally – and perhaps globally – will 
involve an enlarged understanding of Chinese patient flows both inwards and outward, the 
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